美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ERAS近 30 天 5 則 · 第 1 / 1 頁
- Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
- Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
- Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
- Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
- Erasca Reports Second Quarter 2026 Business Updates and Financial Results
- Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
- Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?
- Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers
- Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results
- Erasca Announces Pricing of Upsized Public Offering of Common Stock
- Erasca Announces Proposed Public Offering of $500 Million of Common Stock
- Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
- Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List
- Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
- TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
- Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
- VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
- Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
- Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
- Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。